Pharmaceuticals, Biotechnology and Life Sciences
The Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) approved Bayer’s larotrectinib, under the brand name Vitrakvi, for the treatment of adult and pediatric patients with advanced solid tumors that harbor a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. NTRK gene fusions should be identified by a sufficiently validated test.
Oxford Biomedica plc has appointed Ms. Namrata P Patel to the Board as an Independent Non-Executive Director with immediate effect.
Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability…
Basilea Pharmaceutica Ltd. has reported that promising preclinical data on the anti-cancer activity of its three oncology drug candidates, BAL0891, derazantinib and lisavanbulin, have been presented at the Annual Meeting of the American Association for Cancer Research (AACR) that took place April 8-13, 2022, in New Orleans, USA.
Santhera Pharmaceuticals (SIX: SANN) has appointed Shabir Hasham, MD, as Chief Medical Officer (CMO) and a member of Santhera’s Executive Management team, effective May 1, 2022.
Jackson ImmunoResearch, manufacturer of secondary antibodies and immunoreagents for the life science market, has announces a new range of detection reagents that offer superior imaging quality.
List Biotherapeutics, Inc. (List Bio, President: Jonathan Yongwan Jo), a new venture under the Genome and Company umbrella, has announced plans for a new manufacturing facility in the Fishers Life Science & Innovation Park, Indiana after closing their Series A round investment.
Schreiner MediPharm will showcase its new Smart Blister Wallet, which is extendable from 32 to up to 64 cavities, at this year’s Pharmapack in Paris, on May 18 and 19.
Ribonexus, a biotechnology start-up developing new therapies that can overcome resistance to current targeted therapies in cancer patients has received €2 million ($2.19M) in funds from the French public investment bank Bpifrance.
Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, has entered into an agreement with Takeda to expand an existing collaboration to now include the discovery and development of novel therapeutics for fibrostenotic inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis.